research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
Search
for
Sort by
Research
480-510 / 1000+ results
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
research Comparison of Sequential Cyproterone Acetate/Estrogen Versus Spironolactone/Oral Contraceptive in the Treatment of Hirsutism
Both cyproterone acetate and spironolactone effectively reduce hair growth in women with hirsutism.
research Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
Sorafenib often causes skin side effects, indicating effective cancer treatment.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research N-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulfatase
Scientists found new, better-working inhibitors for a hormone-related enzyme.
research Baricitinib in Alopecia Areata
Baricitinib is not very effective for severe alopecia areata.
research Crystal Structure and Synthesis of 17.ALPHA.-Acetoxy-6,7-epoxypregn-4-ene-3,20-dione
A new compound was made that might help treat diseases related to male hormones.
research Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line‐field confocal optical coherence tomography evaluation
Baricitinib helps with early hair regrowth in people with alopecia areata.
research Inhibition of 5α-Reductase Activity in SZ95 Sebocytes and HaCaT Keratinocytes In Vitro
The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.
research Nano-CoCr2O4 Catalysts Promote the Synthesis of Diamino Pyrimidine Oxide Derivatives
CoCr2O4 catalysts effectively and sustainably produce diaminopyrimidine oxides with high yield.
research Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia
A new drug strategy improves hair loss treatment with better results and safety.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Topical MK-386 (M), an inhibitor of 5α-reductase (5αr) type I, suppresses sebum dht.
MK-386 reduces sebum DHT levels.
research Application of Baricitinib in Dermatology
Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
research Sebaceous carcinoma arising at a chronic candidiasis skin lesion of a patient with keratitis-ichthyosis-deafness (KID) syndrome
A man with KID syndrome developed a rare cancer in a long-term skin infection.
research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells.
Finasteride blocks progesterone production in specific tumor cells, potentially causing side effects.
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata
Baricitinib is effective and safe for treating alopecia areata.
research Antibacterials/corticosteroids/minoxidil
research Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research [Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer].
MVP treatment is effective and safe for recurrent breast cancer.
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research Pharmacological basis for clinical use of antiandrogens
Cyproterone acetate is used to treat conditions like prostate cancer, early puberty, excessive sexual drive, and female androgenization by blocking male sex hormones.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
research Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.
research Repurposing Finasteride and Serotonin Reuptake Inhibitors as Novel Antimicrobials: A Dual-Action Approach to Target Bacterial and Fungal Pathogens
Duloxetine, escitalopram, and finasteride may be effective against bacteria and fungi.
research High-risk cutaneous squamous cell carcinoma in a Japanese allogeneic bone marrow transplant recipient on long-term voriconazole
A Japanese bone marrow transplant patient developed a rare skin cancer possibly linked to long-term use of the medication voriconazole.
research Systemic Antifungals
Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.
research Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.